Bicara Therapeutics
Developing a bifunctional antibody program for head and neck and other solid tumors.
$23.43
After-hours close+0.02 (+0.06%)
At close$23.42(−5.70%)
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | −$0.85 | — | — |
| Aug 2026 | −$0.82 | −$0.82 | 0.0% |
| May 2026 | −$0.64 | −$0.93 | −45.3% |
| Mar 2026 | −$0.72 | −$0.68 | +5.6% |
| Nov 2025 | −$0.55 | −$0.67 | −21.8% |
The latest year is open to everyone — the 10 quarters behind it read with an account. Sign in | |||
| Aug 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Nov 2024 | |||
| Sep 2024 | |||
| Jun 2024 | |||
| Dec 2023 | |||
| Sep 2023 | |||
| Jun 2023 | |||
| Mar 2023 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise |
|---|---|---|---|---|---|---|
| Nov 9, 2026 | −$0.85 | — | — | — | — | — |
| Aug 11, 2026 | −$0.82 | −$0.82 | 0.0% | — | — | — |
| May 11, 2026 | −$0.64 | −$0.93 | −45.3% | — | — | — |
| Mar 26, 2026 | −$0.72 | −$0.68 | +5.6% | — | — | — |
| Nov 10, 2025 | −$0.55 | −$0.67 | −21.8% | — | — | — |
The latest year is open to everyone — the 10 quarters behind it read with an account. Sign in | ||||||
| Aug 12, 2025 | ||||||
| May 13, 2025 | ||||||
| Mar 27, 2025 | ||||||
| Nov 12, 2024 | ||||||
| Sep 13, 2024 | ||||||
| Jun 30, 2024 | ||||||
| Dec 31, 2023 | ||||||
| Sep 30, 2023 | ||||||
| Jun 30, 2023 | ||||||
| Mar 31, 2023 | ||||||